Puma Biotechnology Inc (PBYI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $401.70M
Last updated: Nov 17, 2026 at 11:06 AM ET
Puma Biotechnology Inc (PBYI) Financials: Revenue, Profit and Cash Flow
Puma Biotechnology reported revenue of $228.37M for the fiscal year ended Dec 31, 2025, down 0.9% from the year before. That year, net income was $31.11M with a net margin of 13.6%, operating cash flow was $41.80M and free cash flow was $41.73M. The quarter ended Sep 30, 2026 had revenue of $55.06M and net income of $5.96M.
Revenue and Margins
The operating margin was 16.3% in the fiscal year ended Dec 2025, the highest of the 8 years shown with an operating margin. Over the 8 years to Dec 2025, revenue grew from $27.68M, a compound annual rate of 30.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $228.37M | -0.9% | 74.5% | 16.3% | 13.6% |
| Dec 2024 | $230.47M | -2.2% | 72.1% | 13.4% | 13.1% |
| Dec 2023 | $235.64M | +3.3% | 73.4% | 13.9% | 9.2% |
| Dec 2022 | $228.03M | -9.9% | 75.8% | 10.4% | 0.0% |
| Dec 2021 | $253.16M | +12.5% | 74.8% | 0.5% | -11.5% |
| Dec 2020 | $225.11M | -17.3% | 82.5% | -13.5% | -26.7% |
| Dec 2019 | $272.26M | +8.5% | 86.5% | -14.3% | -27.8% |
| Dec 2018 | $250.99M | +806.6% | 86.2% | -37.7% | -45.3% |
| Dec 2017 | $27.68M | N/A | 79.9% | -1056.1% | -1054.6% |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income rose 2.7% from the year before. In the quarter ended Sep 2026, net income fell 32.6% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228.37M | $230.47M | $235.64M | $228.03M | $253.16M | $225.11M | $272.26M | $250.99M | $27.68M | $0 |
| Cost of revenue | $58.16M | $64.40M | $62.68M | $55.09M | $63.70M | $39.37M | $36.81M | $34.62M | $5.57M | $0 |
| Gross profit | $170.21M | $166.06M | $172.96M | $172.94M | $189.45M | $185.74M | $235.44M | $216.37M | $22.11M | $0 |
| Research and development | $62.07M | $54.94M | $50.38M | $59.24M | $71.87M | $97.65M | $132.85M | $164.85M | $207.81M | $222.80M |
| Operating income | $37.30M | $30.97M | $32.64M | $23.72M | $1.29M | -$30.40M | -$39.05M | -$94.66M | -$292.39M | -$276.60M |
| Net income | $31.11M | $30.28M | $21.59M | $2.00K | -$29.13M | -$59.99M | -$75.59M | -$113.58M | -$291.95M | -$276.01M |
| EBITDA | $49.26M | $43.35M | $44.92M | N/A | $3.30M | N/A | N/A | N/A | -$289.68M | -$272.82M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55.06M | $56.50M | $44.81M | $75.45M | $54.48M | $52.44M | $46.01M | $59.08M | $80.54M | $47.08M | $43.77M | $72.18M |
| Gross profit | $39.86M | $44.03M | $34.39M | $52.33M | $42.30M | $40.13M | $35.45M | $45.16M | $51.45M | $36.42M | $33.04M | $47.85M |
| Operating income | $5.27M | $7.58M | -$3.83M | $17.11M | $9.57M | $6.64M | $3.98M | $13.37M | $22.08M | -$2.18M | -$2.30M | $14.80M |
| Net income | $5.96M | $8.19M | -$3.75M | $13.44M | $8.84M | $5.86M | $2.97M | $19.30M | $20.32M | -$4.53M | -$4.82M | $12.27M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $22.52M by $7.11M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $216.30M | $213.33M | $230.53M | $222.06M | $226.59M | $244.22M | $234.91M | $259.12M | $165.53M | $252.79M |
| Current assets | $162.69M | $147.66M | $156.19M | $134.28M | $140.02M | $146.14M | $166.30M | $203.00M | $106.39M | $236.47M |
| Cash and equivalents | $29.64M | $69.22M | $84.58M | $76.20M | $63.13M | $85.29M | $60.04M | $108.42M | $81.70M | $194.49M |
| Total liabilities | $85.96M | $121.21M | $177.09M | $200.45M | $229.03M | $250.17M | $217.44M | $224.82M | $112.22M | $42.97M |
| Short-term debt | $22.52M | $45.33M | $34.00M | $0 | $3.57M | $14.29M | $0 | N/A | $48.48M | N/A |
| Long-term debt | N/A | $21.72M | $65.66M | $98.31M | $97.09M | $84.03M | $94.96M | $151.89M | $48.48M | $0 |
| Shareholder equity | $130.34M | $92.13M | $53.44M | $21.61M | -$2.45M | -$5.95M | $17.46M | $34.31M | $53.30M | $209.82M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $202.77M | $192.74M | $192.70M | $216.30M | $202.86M | $194.92M | $196.18M | $213.33M | $220.72M | $205.00M | $214.15M | $230.53M |
| Total liabilities | $56.15M | $54.19M | $64.28M | $85.96M | $87.59M | $90.20M | $99.07M | $121.21M | $149.63M | $156.49M | $163.17M | $177.09M |
| Cash and equivalents | $41.55M | $36.54M | $36.19M | $29.64M | $53.52M | $54.66M | $63.03M | $69.22M | $67.26M | $67.15M | $76.75M | $84.58M |
| Shareholder equity | $146.61M | $138.54M | $128.42M | $130.34M | $115.27M | $104.72M | $97.11M | $92.13M | $71.09M | $48.51M | $50.98M | $53.44M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.8% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $41.80M | $38.92M | $27.01M | -$15.83M | $20.65M | $773.00K | $22.38M | -$24.11M | -$172.47M | -$141.69M |
| Capital expenditures | $71.00K | $56.00K | $140.00K | $0 | $0 | $46.00K | $306.00K | $609.00K | $431.00K | $7.28M |
| Free cash flow | $41.73M | $38.86M | $26.87M | -$15.83M | $20.65M | $727.00K | $22.07M | -$24.71M | -$172.90M | -$148.97M |
| Share repurchases | N/A | N/A | N/A | $277.00K | $0 | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | -$36.19M | -$20.44M | -$19.13M | $7.10M | -$10.88M | $33.40M | $5.16M | -$57.62M | -$15.44M | $142.19M |
| Financing cash flow | -$45.20M | -$33.85M | $0 | $12.22M | -$31.93M | -$9.93M | -$67.07M | $108.45M | $75.11M | $162.43M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.58M | $1.62M | $15.42M | $14.42M | $9.69M | $14.08M | $3.61M | $15.61M | $11.04M | $1.03M | $11.25M | $10.46M |
| Capital expenditures | N/A | N/A | $0 | $36.00K | $26.00K | $20.00K | $61.00K | $16.00K | $20.00K | $20.00K | $0 | $45.00K |
| Free cash flow | N/A | N/A | $15.42M | $14.38M | $9.66M | $14.06M | $3.55M | $15.59M | $11.02M | $1.01M | $11.25M | $10.41M |
Frequently Asked Questions About PBYI
What is Puma Biotechnology's annual revenue?
Puma Biotechnology reported revenue of $228.37M for the fiscal year ended Dec 31, 2025.
How fast is Puma Biotechnology's revenue growing?
Revenue was down 0.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.0%.
Is Puma Biotechnology profitable?
Yes. Puma Biotechnology reported net income of $31.11M for the fiscal year ended Dec 31, 2025, with a net margin of 13.6%.
How much free cash flow does PBYI generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $41.80M minus capital expenditures of $71.00K produced free cash flow of $41.73M.
How much debt does Puma Biotechnology have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $22.52M and cash and equivalents of $29.64M.
PBYI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors